Recombinant Human LITAF/PIG7/SIMPLE Protein, N-GST & C-His

Description of Recombinant Human LITAF/PIG7/SIMPLE Protein, N-GST & C-His

Introduction

The Recombinant Human LITAF/PIG7/SIMPLE Protein is a highly purified and biologically active protein that is produced through recombinant DNA technology. This protein is also known as LPS-induced TNF-alpha factor (LITAF), phosphatidylinositol glycan anchor biosynthesis class F protein (PIG7), and small integral membrane protein of lysosome/late endosome (SIMPLE). It plays a crucial role in various cellular processes and has potential applications in both research and therapeutic fields.

Structure of Recombinant Human LITAF/PIG7/SIMPLE Protein

The Recombinant Human LITAF/PIG7/SIMPLE Protein is a 161 amino acid protein with a molecular weight of approximately 18 kDa. It consists of a single transmembrane domain and a C-terminal domain that contains a LITAF domain. The LITAF domain is responsible for the protein’s ability to bind to lipopolysaccharides (LPS) and regulate the production of pro-inflammatory cytokines.

Activity of Recombinant Human LITAF/PIG7/SIMPLE Protein

The Recombinant Human LITAF/PIG7/SIMPLE Protein is primarily involved in the regulation of immune and inflammatory responses. It is known to activate the NF-kB signaling pathway and induce the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6. This protein also plays a role in the regulation of autophagy, a cellular process that helps maintain cellular homeostasis by degrading damaged or unnecessary components.

In addition to its role in immune and inflammatory responses, the Recombinant Human LITAF/PIG7/SIMPLE Protein has been found to have anti-tumor activity. It has been shown to inhibit the growth of certain cancer cells and induce apoptosis, or programmed cell death, in these cells. This makes it a potential target for cancer therapy.

Application of Recombinant Human LITAF/PIG7/SIMPLE Protein

The Recombinant Human LITAF/PIG7/SIMPLE Protein has a wide range of applications in both research and therapeutic fields. In research, it is commonly used as an antigen in studies related to immune and inflammatory responses, autophagy, and cancer. Its ability to regulate the production of pro-inflammatory cytokines makes it a valuable tool in understanding various diseases and developing potential treatments.

In the therapeutic field, the Recombinant Human LITAF/PIG7/SIMPLE Protein has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis and sepsis. It can also be utilized in cancer therapy as a potential anti-tumor agent. Furthermore, this protein has been studied for its potential role in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.

Conclusion

The Recombinant Human LITAF/PIG7/SIMPLE Protein is a biologically active protein with a crucial role in immune and inflammatory responses. Its structure, activity, and potential applications make it a valuable tool in both research and therapeutic fields. With ongoing studies and advancements in recombinant DNA technology, this protein holds promise for future developments in the treatment of various diseases.